Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 3:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 200 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adenovirus Infection Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers

NCT04591717
View directory record Official record
Conditions
COVID-19
Interventions
hAd5-S-Fusion+N-ETSD vaccine
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
El Segundo, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Jul 21, 2026, 3:54 PM EDT
Withdrawn Phase 1 Interventional

Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A)

NCT02276820
View directory record Official record
Conditions
Adenovirus Infection
Interventions
Viralym-A
Biological
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2018 · Synced Jul 21, 2026, 3:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects

NCT04563702
View directory record Official record
Conditions
Covid19
Interventions
VXA-CoV2-1
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 54 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Jul 21, 2026, 3:54 PM EDT
Recruiting Phase 1Phase 2 Interventional

Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity

NCT06909110
View directory record Official record
Conditions
Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections
Interventions
Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, Epstein-Barr Virus Specific T-Lymphocytes
Biological
Lead sponsor
Jessie L. Alexander
Other
Eligibility
1 Month to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Jul 21, 2026, 3:54 PM EDT
Completed Phase 1 Interventional Results available

Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma

NCT03072134
View directory record Official record
Conditions
Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Glioblastoma Multiforme, Astrocytoma, Grade III, Astrocytoma, Grade IV, Brain Cancer
Interventions
Neural stem cells loaded with an oncolytic adenovirus
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Duarte, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Jul 21, 2026, 3:54 PM EDT
Completed Phase 1 Interventional

Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer

NCT01972737
View directory record Official record
Conditions
Colon Cancer
Interventions
Ad5-hGCC-PADRE vaccine
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Jul 21, 2026, 3:54 PM EDT
Completed Phase 1 Interventional

Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)

NCT01945814
View directory record Official record
Conditions
EBV, CMV, Adenovirus
Interventions
CTL for CMV seropositive donors, CTL for CMV naïve donors
Drug
Lead sponsor
Catherine Bollard
Other
Eligibility
4 Weeks to 45 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Jul 21, 2026, 3:54 PM EDT
Recruiting Phase 1 Interventional

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

NCT03896568
View directory record Official record
Conditions
IDH1 wt Allele, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Malignant Glioma
Interventions
Oncolytic Adenovirus Ad5-DNX-2401, Therapeutic Conventional Surgery
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 21, 2026, 3:54 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT

NCT03665675
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Cytomegalovirus, Donor, Solid Organ Transplantation Recipient, Adenovirus
Interventions
Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes, Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
Biological
Lead sponsor
Sumithira Vasu
Other
Eligibility
1 Year to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 21, 2026, 3:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

NCT02685020
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos.HIV, Clade C gp140, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jul 21, 2026, 3:54 PM EDT
Completed Phase 1 Interventional

Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma

NCT00005057
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
adenovirus RSV-TK, ganciclovir
Biological · Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
3
States / cities
Bethesda, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Jul 21, 2026, 3:54 PM EDT
Terminated Phase 3 Interventional Results available

Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

NCT05179057
View directory record Official record
Conditions
Adenovirus Infection
Interventions
Posoleucel, Placebo
Drug
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
23
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Jul 21, 2026, 3:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults

NCT00384787
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA009-00-VP, VRC-HIVADV014-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
6
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Jul 21, 2026, 3:54 PM EDT
Suspended Phase 1 Interventional

DNX-2440 for Resectable Colorectal Liver Metastasis

NCT04714983
View directory record Official record
Conditions
Liver Metastases, Liver Metastasis Colon Cancer, Colorectal Cancer, Breast Cancer, Gastric Cancer, Periampullary Cancer, Melanoma, Renal Cell Cancer, Sarcoma, Squamous Cell Carcinoma, Gastrointestinal Stromal Tumors
Interventions
DNX-2440
Biological
Lead sponsor
DNAtrix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Jul 21, 2026, 3:54 PM EDT
Completed Phase 1Phase 2 Interventional Results available

ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus

NCT01570283
View directory record Official record
Conditions
Viral Infection
Interventions
Multivirus-specific T cells Dose Level 1, Multivirus-specific T cells Dose Level 2, Multivirus-specific T cells Dose Level 3
Biological
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Jul 21, 2026, 3:54 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection

NCT06999603
View directory record Official record
Conditions
Viral Pneumonia
Interventions
SNG001, Placebo
Drug
Lead sponsor
Synairgen Research Ltd.
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
22
States / cities
Sacramento, California • Torrance, California • Naples, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Jul 21, 2026, 3:54 PM EDT
Completed Phase 1 Interventional

First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector

NCT04053283
View directory record Official record
Conditions
Metastatic Cancer, Epithelial Tumor
Interventions
NG-641
Biological
Lead sponsor
Akamis Bio
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Santa Barbara, California • Celebration, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Jul 21, 2026, 3:54 PM EDT
Terminated Phase 2 Interventional Results available

Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT00849524
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
ISF35
Biological
Lead sponsor
Januario Castro, M.D.
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Jul 21, 2026, 3:54 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV

NCT04364178
View directory record Official record
Conditions
Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus
Interventions
Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, EBV Specific T-Lymphocytes
Biological
Lead sponsor
Jessie L. Alexander, MD
Other
Eligibility
1 Month to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 21, 2026, 3:54 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer

NCT03754933
View directory record Official record
Conditions
Recurrent Head and Neck Cancer
Interventions
Ad/PNP, Fludarabine Phosphate
Biological · Drug
Lead sponsor
GeoVax, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Stanford, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Jul 21, 2026, 3:54 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21

NCT00583752
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
Adenovirus/PSA Vaccine
Biological
Lead sponsor
David M Lubaroff
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Jul 21, 2026, 3:54 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

NCT01397708
View directory record Official record
Conditions
Melanoma
Interventions
INXN-2001, INXN-1001
Biological · Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
9
States / cities
Los Angeles, California • Park Ridge, Illinois • Goshen, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jul 21, 2026, 3:54 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals

NCT03964415
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos4.HIV, Clade C and Mosaic gp140 HIV bivalent vaccine, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 60 Years
Enrollment
3,900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Jul 21, 2026, 3:54 PM EDT
Recruiting Phase 1 Interventional

Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.

NCT05686798
View directory record Official record
Conditions
Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme, GBM
Interventions
Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)
Biological
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Jul 21, 2026, 3:54 PM EDT